Emerging nanoparticle platforms to improve the administration of glucocorticoids

Glucocorticoids (GC) are common drugs used to treat acute and chronic inflammatory diseases, whose prolonged use can result in severe side effects hampering their efficacy. In addition, the pharmacokinetics, and biodistribution of GC are inadequate to support high efficacy with reduced toxicity. Fol...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of controlled release 2023-06, Vol.358, p.273-292
Hauptverfasser: Tessier, Barbara, Tsapis, Nicolas, Fattal, Elias, Moine, Laurence
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Glucocorticoids (GC) are common drugs used to treat acute and chronic inflammatory diseases, whose prolonged use can result in severe side effects hampering their efficacy. In addition, the pharmacokinetics, and biodistribution of GC are inadequate to support high efficacy with reduced toxicity. Following the marketing of GC prodrugs, new GC prodrug entities, and conjugates, have been developed. These new prodrugs and conjugates have been administered in free form or under a nanoparticulate form for local or systemic administration. These nanoparticles from lipid prodrugs and nanoconjugates change the paradigm of GC delivery, solving the issue of low drug loading into nanoparticles and circumventing the potential burst release effect by allowing a more controlled delivery of the GC and better targeting in inflammatory sites. This review highlights the design strategies, recent advances in GC prodrugs and conjugates, and their delivery in nanoparticulate form, demonstrating the strong potentialities of these novel strategies. [Display omitted] •Nanoparticles from lipid prodrugs and nanoconjugates allow high drug loading and controlled release of glucocorticoids.•Nanoparticles from lipid prodrugs and nanoconjugates better target inflammation sites in of several inflammatory diseases.•Inflammation-responsive delivery systems hold great promise for spatio-temporal control of glucocorticoid delivery.
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2023.04.039